TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06679270: An Open-label Extension of APG-20 Study to Evaluate the Long-term Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With Partial Lipodystrophy

Sponsor: Chiesi Farmaceutici S.p.A. · Phase: PHASE3 · Area: RARE_ORPHAN · Target Enrollment: 24 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$877,560

Rescue Site Savings

+$585,040

Unlock Full NCT06679270 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06679270 Rescue Dossier →